Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyamemazine
- Development stage
- Unknown
- Lead developer
- Theraplix
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Cyamemazine is a typical antipsychotic drug of the phenothiazine class, primarily used in the treatment of schizophrenia and psychosis-associated anxiety. Despite its classification as a typical antipsychotic, it exhibits properties similar to atypical antipsychotics due to its potent anxiolytic effects and low risk of extrapyramidal side effects. Cyamemazine acts as an antagonist at multiple receptors, including dopamine D1–D4 receptors, serotonin 5-HT2A, 5-HT2C, 5-HT3, and 5-HT7 receptors, histamine H1 receptor, muscarinic acetylcholine M1–M5 receptors, and alpha1 adrenergic receptor. Its unique profile—especially strong antagonism at serotonin 5‑HT2A/2C/7—contributes to its anxiolytic action and reduced motor side effects compared to other phenothiazines. It was introduced by Theraplix in France[4][6].
- Brand names
- Tercian
- Other names
- cyamemazine monohydrochloridecyamemazine tartrate
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)HTR7 (5-hydroxytryptamine receptor 7)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)
Beyond the preview
Go deeper on cyamemazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyamemazine.